$67.47
00.00%
Pre-Market: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
PROCEPT BioRobotics
PRCTNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
PROCEPT BioRobotics (NASDAQ:PRCT) Stock, Analyst Ratings, Price Targets, Forecasts
PROCEPT BioRobotics Corp has a consensus price target of $51.31 based on the ratings of 15 analysts. The high is $79 issued by Truist Securities on July 16, 2024. The low is $30 issued by SVB Leerink on March 9, 2022. The 3 most-recent analyst ratings were released by Truist Securities, TD Cowen, and Piper Sandler on July 16, 2024, May 6, 2024, and May 6, 2024, respectively. With an average price target of $76.33 between Truist Securities, TD Cowen, and Piper Sandler, there's an implied 13.14% upside for PROCEPT BioRobotics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
TD Cowen
Piper Sandler
Wells Fargo
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for PROCEPT BioRobotics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 17.09% | Truist Securities | Richard Newitter | $72 → $79 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 11.16% | TD Cowen | Joshua Jennings | $65 → $75 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 11.16% | Piper Sandler | Matt O'Brien | $67 → $75 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 6.71% | Truist Securities | Richard Newitter | $63 → $72 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | -14.04% | Truist Securities | Richard Newitter | $55 → $58 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | -30.34% | Wells Fargo | Nathan Treybeck | $44 → $47 | Maintains | Overweight | Get Alert |
| 12/22/2023 | Buy Now | -25.89% | Truist Securities | Richard Newitter | $48 → $50 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | -34.79% | Wells Fargo | Nathan Treybeck | $40 → $44 | Maintains | Overweight | Get Alert |
| 10/16/2023 | Buy Now | -45.16% | Leerink Partners | Mike Kratky | → $37 | Initiates | → Outperform | Get Alert |
| 09/13/2023 | Buy Now | -27.38% | Truist Securities | Richard Newitter | → $49 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | -37.75% | Piper Sandler | Matt O'Brien | → $42 | Initiates | → Overweight | Get Alert |
| 05/31/2023 | Buy Now | — | William Blair | Brandon Vazquez | — | Initiates | → Outperform | Get Alert |
| 05/01/2023 | Buy Now | -27.38% | Truist Securities | Richard Newitter | $54 → $49 | Maintains | Buy | Get Alert |
| 05/01/2023 | Buy Now | -30.34% | Keybanc | Matthew Mishan | $48 → $47 | Maintains | Overweight | Get Alert |
| 04/28/2023 | Buy Now | -34.79% | B of A Securities | Craig Bijou | $52 → $44 | Maintains | Buy | Get Alert |
| 04/28/2023 | Buy Now | -27.38% | Truist Securities | Richard Newitter | $54 → $49 | Maintains | Buy | Get Alert |
| 01/31/2023 | Buy Now | -18.48% | Truist Securities | Richard Newitter | $58 → $55 | Maintains | Buy | Get Alert |
| 01/12/2023 | Buy Now | -36.27% | Wells Fargo | Nathan Treybeck | $52 → $43 | Maintains | Overweight | Get Alert |
| 12/12/2022 | Buy Now | -22.93% | Wells Fargo | Nathan Treybeck | $49 → $52 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | -34.79% | Goldman Sachs | Amit Hazan | $39 → $44 | Maintains | Neutral | Get Alert |
| 11/04/2022 | Buy Now | -28.86% | Keybanc | Matthew Mishan | $47 → $48 | Maintains | Overweight | Get Alert |
| 10/31/2022 | Buy Now | — | BTIG | Ryan Zimmerman | — | Initiates | → Neutral | Get Alert |
| 10/25/2022 | Buy Now | -14.04% | Truist Securities | Richard Newitter | → $58 | Initiates | → Buy | Get Alert |
| 09/02/2022 | Buy Now | -27.38% | Wells Fargo | Nathan Treybeck | → $49 | Initiates | → Overweight | Get Alert |
| 07/15/2022 | Buy Now | -30.34% | Keybanc | Matthew Mishan | → $47 | Initiates | → Overweight | Get Alert |
| 03/09/2022 | Buy Now | -37.75% | B of A Securities | Craig Bijou | $48 → $42 | Maintains | Buy | Get Alert |
| 03/09/2022 | Buy Now | -55.54% | SVB Leerink | Danielle Antalffy | $25 → $30 | Maintains | Outperform | Get Alert |
| 11/05/2021 | Buy Now | -18.48% | SVB Leerink | Danielle Antalffy | — | Maintains | Outperform | Get Alert |
| 10/11/2021 | Buy Now | -28.86% | B of A Securities | Bob Hopkins | — | Initiates | → Buy | Get Alert |
| 10/11/2021 | Buy Now | -25.89% | Cowen & Co. | Joshua Jennings | — | Initiates | → Outperform | Get Alert |
| 10/11/2021 | Buy Now | -33.3% | Guggenheim | Chris Pasquale | — | Initiates | → Buy | Get Alert |
| 10/11/2021 | Buy Now | -31.82% | SVB Leerink | — | — | Initiates | → Outperform | Get Alert |
| 10/11/2021 | Buy Now | -45.16% | Goldman Sachs | Amit Hazan | — | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for PROCEPT BioRobotics (PRCT) stock?
The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Truist Securities on July 16, 2024. The analyst firm set a price target for $79.00 expecting PRCT to rise to within 12 months (a possible 17.09% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for PROCEPT BioRobotics (PRCT)?
The latest analyst rating for PROCEPT BioRobotics (NASDAQ:PRCT) was provided by Truist Securities, and PROCEPT BioRobotics maintained their buy rating.
When was the last upgrade for PROCEPT BioRobotics (PRCT)?
There is no last upgrade for PROCEPT BioRobotics
When was the last downgrade for PROCEPT BioRobotics (PRCT)?
There is no last downgrade for PROCEPT BioRobotics.
When is the next analyst rating going to be posted or updated for PROCEPT BioRobotics (PRCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PROCEPT BioRobotics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PROCEPT BioRobotics was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating PROCEPT BioRobotics (PRCT) correct?
While ratings are subjective and will change, the latest PROCEPT BioRobotics (PRCT) rating was a maintained with a price target of $72.00 to $79.00. The current price PROCEPT BioRobotics (PRCT) is trading at is $67.47, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.